FDA Approves Atezolizumab Based on Results from the Phase III ATOMIC Trial for Patients with Stage III dMMR Colon Cancer

The Alliance for Clinical Trials in Oncology (Alliance) today announced that the U.S. Food and Drug Administration has approved the immunotherapy drug atezolizumab (Tecentriq®) in combination with fluoropyrimidine and oxaliplatin chemotherapy, for the adjuvant treatment of patients with stage III colon cancer with deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR). The approval is based on findings from the phase III Alliance ATOMIC (A021502) trial, sponsored by the National Can


UPCOMING MEETINGS

Upcoming Group Meetings
- November 4-6, 2026  Registration | Meeting Schedule
- May 19-21, 2027

All meetings will be held at the Loews Chicago O'Hare Hotel in Rosemont, IL and are open to all Alliance members.
 

IN THE NEWS


ALLIANCE ON SOCIAL

FROM THE NCI